Clinical Trial

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Study acronym: IMPACT 1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study team's principal interest is to address the question, "Will prophylactic treatment with mesalamine reduce the incidence and severity of immune-related diarrhea occurring secondarily to treatment with ipi/nivo?"
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-12-15; most recent amendment 2025-06-24.
Status change: Not Yet Recruiting → Recruiting 2025-06-24
Trial Details
NCT Number NCT05663775
Lead Sponsor AHS Cancer Control Alberta
Conditions Immune-related Adverse Event, Diarrhea, Advanced Melanoma, Advanced Rectal Carcinoma
Enrollment 20 participants
Start Date 2024-08-20
Primary Completion 2026-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-06-27